Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug

Executive Summary

Animal model results for Human Genome Sciences' raxibacumab are predictive of the biologics' ability to treat inhalation anthrax in humans, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 27, but FDA should request more evidence on whether the monoclonal antibody adds benefit to treatment with antibiotics alone

You may also be interested in...



FDA Advisory Cmte. Loosens Statistical Significance Standard, Waves GSK’s Anthrax Drug Through

An additional animal study that Human Genome Sciences did after receiving a “complete response” letter from FDA showed clinical benefit for raxibacumab, but with a p-value higher than the standard maximum value of 0.05.

GSK’s Anthrax Treatment Raxibacumab Gets Second Chance To Be First Animal Rule NME

FDA’s Anti-Infective Drugs Advisory Committee will have new pharmacokinetic data to review when it meets Nov. 2 to discuss the monoclonal antibody, which targets the anthrax toxin rather than the pathogen.

Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products

When an FDA advisory panel gave its enthusiastic backing to the strategy for anthrax vaccine research developed by the agency's Center for Biologics Evaluation and Research, it also provided an important precedent for future applications of the "animal rule," which allows sponsors to conduct animal trials when human clinical trials would be impractical or unethical.

Related Content

Topics

UsernamePublicRestriction

Register

PS051625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel